OSI Systems, Inc. Form 10-Q Summary
Reporting period: Quarterly period ended March 31, 2021; fiscal third quarter of fiscal 2021. The supplied metadata labels the period “2020 Q3,” but the filing reports Q3 fiscal 2021 and compares it with the quarter ended March 31, 2020. Results are unaudited and amounts are generally in thousands unless stated otherwise.
Business Context
OSI Systems designs and manufactures specialized electronic systems and components for security and inspection, healthcare, defense, aerospace and related markets. Its operating divisions are Security, Healthcare, and Optoelectronics and Manufacturing.
Financial Performance and Position
| Metric | Three months ended March 31, 2021 | Three months ended March 31, 2020 | Change |
|---|---|---|---|
| Net revenues | $283.8 million | $292.9 million | Down 3% |
| Gross profit | $104.0 million | $109.1 million | Down 5% |
| Gross margin | 36.7% | 37.3% | Down 60 basis points |
| Income from operations | $32.5 million | $23.6 million | Up 37% |
| Net income | $18.8 million | $19.6 million | Down 4% |
| Diluted earnings per share | $1.03 | $1.06 | Down 3% |
| Effective tax rate | 33.7% | (3.4)% | Higher tax burden |
| Metric | Nine months ended March 31, 2021 | Nine months ended March 31, 2020 | Change |
|---|---|---|---|
| Net revenues | $814.7 million | $889.1 million | Down 8% |
| Gross profit | $301.9 million | $319.1 million | Down 5% |
| Gross margin | 37.1% | 35.9% | Up 120 basis points |
| Income from operations | $81.5 million | $81.4 million | Approximately flat |
| Net income | $48.2 million | $61.3 million | Down 21% |
| Diluted earnings per share | $2.63 | $3.28 | Down 20% |
| Effective tax rate | 30.1% | 8.7% | Higher tax burden |
- Quarterly segment revenue: Security revenue was $151.4 million, down 19%; Healthcare revenue was $54.0 million, up 18%; and Optoelectronics and Manufacturing revenue was $78.4 million, up 30%.
- Year-to-date segment revenue: Security revenue was $431.4 million, down 25%; Healthcare revenue was $160.4 million, up 25%; and Optoelectronics and Manufacturing revenue was $222.9 million, up 22%.
- Cash flow: Nine-month operating cash flow was $131.1 million, compared with $105.6 million in the prior-year period. Investing cash use was $26.2 million, and financing cash use was $91.4 million.
- Cash and liquidity: Cash and cash equivalents were $92.5 million at March 31, 2021, up from $76.1 million at June 30, 2020. Approximately 58% of cash was held by foreign subsidiaries and may be subject to repatriation tax considerations.
- Debt: The company had $274.9 million of long-term debt, primarily the $287.5 million principal amount of 1.25% convertible senior notes due September 1, 2022. There were no borrowings under the $535 million revolving credit facility, $66.7 million of letters of credit outstanding, and $468.3 million available to borrow.
- Balance sheet: Total assets were $1.326 billion and stockholders’ equity was $615.9 million at March 31, 2021. Inventories increased to $283.5 million from $241.2 million at June 30, 2020.
Material Changes Versus the Prior Comparable Period
- Security revenue declined because COVID-19 delayed aviation and cargo equipment deliveries, installations, services and new orders. Year-to-date cargo revenue decreased by approximately $67 million, advanced security screening revenue decreased by approximately $34 million, and the expired Mexico turnkey contract reduced revenue by approximately $50 million.
- Healthcare revenue benefited from increased demand for patient monitoring, cardiology equipment, supplies and related services, including demand associated with COVID-19.
- Optoelectronics and Manufacturing revenue increased due to growth in contract manufacturing and optoelectronics sales.
- Quarterly gross margin declined because of an unfavorable Optoelectronics and Manufacturing sales mix and its larger share of consolidated revenue. Year-to-date gross margin improved due to stronger Healthcare margins, a greater Healthcare revenue mix and improved Security service margins.
- Operating expenses declined due to lower travel, marketing, compensation and sales commissions, partly offset by higher provisions for accounts receivable losses. Quarterly operating income improved as the prior-year period included a $3.3 million Healthcare product-line impairment and other charges.
- Year-to-date impairment, restructuring and other charges increased to $7.9 million from $1.5 million, primarily because of $7.2 million of exit activities associated with the expired Mexico turnkey contract.
- Net income and earnings per share declined primarily because the prior-year period included significant discrete tax benefits, while fiscal 2021 included higher tax expense. Nine-month income tax expense was $20.8 million versus $5.9 million.
- The company repurchased 322,588 shares during the nine months ended March 31, 2021. The repurchase authorization permits up to 3 million shares, with approximately 2.7 million shares remaining at March 31, 2021.
Guidance, Outlook, Risks and Unusual Items
- The filing does not provide specific quantitative revenue, earnings or margin guidance. Management expects available funds, credit facilities and operating cash flow to meet operational needs for the next 12 months and the foreseeable future.
- Management reported accelerated bookings during the first nine months of fiscal 2021, but expects COVID-19-related delays, customer delivery changes, factory or site acceptance testing delays and supply-chain disruptions to continue affecting revenue timing.
- Remaining performance obligations were approximately $322.8 million at March 31, 2021; approximately 67% was expected to be recognized over the following 12 months.
- Material risks include the duration and effects of COVID-19, global economic and trade uncertainty, government procurement and budget changes, contract renewals and customer acceptance delays, foreign currency movements, tax-law changes, supply-chain interruptions, export and environmental compliance, and legal or regulatory investigations.
- The SEC and DOJ continue investigations related to trading in company securities and information concerning operations and disclosures. The company cannot predict potential actions, penalties or remedial measures.
- The company is defending securities class actions and shareholder derivative litigation related to allegations in a prior short-seller report. Outcomes and potential losses cannot currently be estimated.
- Environmental investigations continue at the Hawthorne, California facility. No liability has been accrued because management believes an unfavorable outcome is not probable and reasonably estimable; an adverse resolution could nevertheless be material.
- Acquisition-related contingent consideration had a fair value of $19.3 million at March 31, 2021, with up to $30.2 million of additional potential payments under capped arrangements.
- On April 28, 2021, after the reporting period, the Compensation Committee amended the CEO long-term incentive program to extend it through fiscal 2023 and increase potential additional share awards based on compound annual operating income growth.
Important Facts for Investors to Verify
- Confirm the period designation: the filing is for the quarter ended March 31, 2021, not Q3 2020.
- Assess whether Security revenue and margins recover as aviation, cargo and EU airport screening activity normalizes, including the revised March 2024 ECAC Standard 3 deadline.
- Monitor inventory growth, accounts receivable provisions and the timing of remaining performance obligations.
- Evaluate liquidity relative to the $287.5 million convertible notes maturity in September 2022, foreign-held cash and outstanding letters of credit.
- Separate recurring operating performance from the effects of COVID-19, Mexico contract exit costs, legal reimbursements, restructuring charges and discrete tax items.
- Track the SEC and DOJ investigations, related shareholder litigation and the unaccrued Hawthorne environmental contingency.
- Review the impact of the CEO incentive-plan amendment and potential dilution from equity awards and convertible notes.